Light Sciences Oncology
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.lsoncology.com/
Clinical Trials
7
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2014-12-29
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Light Sciences Oncology
- Target Recruit Count
- 225
- Registration Number
- NCT02326454
Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
- Conditions
- Benign Prostatic HyperplasiaLower Urinary Tract Symptoms
- Interventions
- Device: Transurethral illumination with light emitting diodesProcedure: Placement
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Light Sciences Oncology
- Target Recruit Count
- 21
- Registration Number
- NCT00918034
- Locations
- 🇦🇺
Royal Brisbane and Women's Hospital Center of Clinical Research, Herston, Australia
🇦🇺Bayside Urology, Mentone, Australia
🇦🇺Princess Alexandra Hospital, Wolloongabba, Australia
Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
- Conditions
- Benign Prostatic HyperplasiaLower Urinary Tract Symptoms
- Interventions
- Procedure: Placement of device in prostate urethraDevice: Transurethral illumination with light emitting diodes (Litx™ BPH Device)
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Light Sciences Oncology
- Target Recruit Count
- 12
- Registration Number
- NCT00709488
- Locations
- 🇺🇸
Alaska Clinical Research Center, Anchorage, Alaska, United States
🇺🇸UCLA School of Medicine, GU Clinical Trials Office, Los Angeles, California, United States
🇺🇸The Portland Clinic, Portland, Oregon, United States
Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
- Conditions
- Liver MetastasesNeoplasm MetastasisColorectal NeoplasmsNeoplasm Recurrence, Local
- Interventions
- Drug: FOLFOX4 regimenProcedure: Percutaneous placement of device in liver metastasesDevice: Interstitial light emitting diodesDrug: FOLFIRI regimen
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Light Sciences Oncology
- Target Recruit Count
- 483
- Registration Number
- NCT00440310
- Locations
- 🇦🇹
Landeskrankenhaus Feldkirch, Feldkirch, Austria
🇦🇹Krankenhaus Hietzing mit Neurologischen Zentrum Rosenhugel, Wien, Austria
🇧🇦Clinical Hospital Mostar, Internal Clinic, Department of Gastroenterology, Mostar, Bosnia and Herzegovina
Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma
- Conditions
- GliomaGlioblastoma MultiformeAnaplastic Astrocytoma
- First Posted Date
- 2006-12-08
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Light Sciences Oncology
- Target Recruit Count
- 18
- Registration Number
- NCT00409214
- Locations
- 🇷🇸
Institute of Neurosurgery, Clinical Centre Serbia, Belgrade, Serbia
- Prev
- 1
- 2
- Next